Cecilia Radkiewicz

Researcher in Cancer Pharmacoepidemiology, Centre for Pharmacoepidemiology (2026–present)
Medical Oncologist, Capio S:t Göran's Hospital (2022–present)
Postdoctoral Researcher in Cancer Epidemiology, Research Group of Jesper Lagergren (2022–2025)
Director of Studies, Research School in Epidemiology for Clinicians (2020–2022)

I hold a combined position conducting research in cancer pharmacoepidemiology at Karolinska Institutet while working clinically as a medical oncologist at Capio S:t Göran's Hospital. My research focuses on cancer epidemiology, pharmacoepidemiology, and outcomes research using large-scale population-based data sources.

Qualifications

• 2025 – Docent (Associate Professor) in Cancer and Oncology, Karolinska Institutet
• 2019 – PhD in Medical Science, Karolinska Institutet
• 2018 – Specialist Certification in Medical Oncology, Sweden
• 2010 – Medical Licensure, Sweden
• 2008 – Bachelor of Medical Science, Karolinska Institutet

My research focuses on cancer epidemiology and cancer pharmacoepidemiology, with particular emphasis on the effectiveness, safety, and long-term outcomes of cancer treatments in routine clinical practice. I use large-scale population-based data from Swedish and Nordic healthcare and demographic registers to study cancer incidence, treatment patterns, survival, and adverse outcomes across patient groups and over time.

Methodologically, I apply advanced epidemiological and statistical approaches, including relative survival methods and flexible parametric regression models, to quantify cancer mortality and evaluate treatment outcomes. I also have a strong interest in developing accessible and interactive ways of communicating research findings to clinicians, researchers, and patients.

I am the principal investigator of the Swedish Anti-Cancer Therapy (SeACT) project, a nationwide academic initiative established to create a comprehensive infrastructure for pharmacoepidemiological research on systemic anti-cancer treatment in Sweden.

SeACT combines information on anti-cancer therapies from the Swedish electronic requisition systems CytoBase, Cytodos, and Mosaiq with data from the National Prescribed Drug Register, the Swedish Cancer Register, and several nationwide health and demographic registers. The resulting resource enables population-based studies of treatment effectiveness, safety, accessibility, and long-term outcomes in routine clinical practice.

During 2026, nationwide data collection from the requisition systems was completed, and linkage with national registers was finalized. Extensive data quality assessments have been performed, and current work focuses on data harmonization, validation, and the development of a national research database. Preliminary analyses for the first planned studies are currently underway.

The long-term aim of SeACT is to establish a national platform for real-world evidence generation in oncology, complementing findings from clinical trials and supporting data-driven cancer care in Sweden.